{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:37:49Z","timestamp":1785253069880,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40264-024-01466-w","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T17:08:46Z","timestamp":1720544926000},"page":"1235-1243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Calculated Risk: Evaluation of QTc Drug\u2013Drug Interaction (DDI) Clinical Decision Support (CDS) Alerts and Performance of the Tisdale Risk Score Calculator"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2044-9408","authenticated-orcid":false,"given":"Rachel L.","family":"Wasserman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane L.","family":"Seger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary G.","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Y.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Fiskio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"16","key":"1466_CR1","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1001\/jama.289.16.2120","volume":"289","author":"SM Al-Khatib","year":"2003","unstructured":"Al-Khatib SM, LaPointe NMA, Kramer JM, et al. What clinicians should know about the QT interval. JAMA. 2003;289(16):2120\u20137. https:\/\/doi.org\/10.1001\/jama.289.16.2120.","journal-title":"JAMA"},{"issue":"1","key":"1466_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1055\/s-0041-1740483","volume":"13","author":"S Stettner","year":"2022","unstructured":"Stettner S, Adie S, Hanigan S, et al. Effect of replacing vendor QTc alerts with a custom QTc risk alert in inpatients. Appl Clin Inform. 2022;13(1):19\u201329. https:\/\/doi.org\/10.1055\/s-0041-1740483.","journal-title":"Appl Clin Inform"},{"issue":"4","key":"1466_CR3","first-page":"268","volume":"65","author":"KA Grindrod","year":"2019","unstructured":"Grindrod KA, Nagge J. Simplifying QT prolongation for busy clinicians. Can Fam Physician. 2019;65(4):268\u201370.","journal-title":"Can Fam Physician"},{"issue":"1","key":"1466_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/1060028020934718","volume":"55","author":"ZR Noel","year":"2021","unstructured":"Noel ZR, See VY, Flannery AH. Walk the line-the importance of well-informed interpretation of QT prolongation. Ann Pharmacother. 2021;55(1):123\u20136. https:\/\/doi.org\/10.1177\/1060028020934718.","journal-title":"Ann Pharmacother"},{"issue":"1149","key":"1466_CR5","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","volume":"97","author":"R Khatib","year":"2021","unstructured":"Khatib R, Sabir FRN, Omari C, Pepper C, Tayebjee MH. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021;97(1149):452\u20138. https:\/\/doi.org\/10.1136\/postgradmedj-2020-138661. (Epub 2020 Oct 29).","journal-title":"Postgrad Med J"},{"key":"1466_CR6","unstructured":"American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology; Council on Cardiovascular Nursing; American College of Cardiology Foundation. Drew B J, Ackerman M J, Funk M. Prevention of Torsade de Pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55(09):934\u2013947."},{"issue":"13","key":"1466_CR7","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","volume":"67","author":"PJ Schwartz","year":"2016","unstructured":"Schwartz PJ, Woosley RL. Predicting the unpredictable: drug-induced QT prolongation and Torsades de Pointes. J Am Coll Cardiol. 2016;67(13):1639\u201350. https:\/\/doi.org\/10.1016\/j.jacc.2015.12.063.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1466_CR8","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/bcp.15580","volume":"89","author":"KM Muylle","year":"2023","unstructured":"Muylle KM, van Laere S, Pannone L, et al. Added value of patient- and drug-related factors to stratify drug\u2013drug interaction alerts for risk of QT prolongation: development and validation of a risk prediction model. Br J Clin Pharmacol. 2023;89(4):1374\u201385. https:\/\/doi.org\/10.1111\/bcp.15580.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1466_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/phar.2400","volume":"40","author":"K Su","year":"2020","unstructured":"Su K, McGloin R, Gellatly RM. Predictive validity of a QTc interval prolongation risk score in the intensive care unit. Pharmacotherapy. 2020;40(6):492\u20139. https:\/\/doi.org\/10.1002\/phar.2400.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"1466_CR10","first-page":"479","volume":"6","author":"JE Tisdale","year":"2013","unstructured":"Tisdale JE, Jaynes HA, Kingery JR, et al. Clinician responses to a clinical decision support advisory for high-risk torsade\u2019s de pointes. JAMA. 2013;6(4):479\u201387.","journal-title":"JAMA"},{"key":"1466_CR11","doi-asserted-by":"publisher","unstructured":"Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients [published correction appears in Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):e57]. Circ Cardiovasc Qual Outcomes. 2013;6(4):479\u2013487. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.113.000152","DOI":"10.1161\/CIRCOUTCOMES.113.000152"},{"key":"1466_CR12","doi-asserted-by":"publisher","unstructured":"Tisdale JE, Jaynes HA, Kingery JR, et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients [published correction appears in Circ Cardiovasc Qual Outcomes. 2014 Nov;7(6):981]. Circ Cardiovasc Qual Outcomes. 2014;7(3):381\u2013390. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.113.000651","DOI":"10.1161\/CIRCOUTCOMES.113.000651"},{"issue":"3","key":"1466_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1715163516641136","volume":"149","author":"JE Tisdale","year":"2016","unstructured":"Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016;149(3):139\u201352. https:\/\/doi.org\/10.1177\/1715163516641136.","journal-title":"Can Pharm J (Ott)."},{"key":"1466_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jelectrocard.2022.11.008","volume":"77","author":"MS Tan","year":"2023","unstructured":"Tan MS, Heise CW, Gallo T, et al. Relationship between a risk score for QT interval prolongation and mortality across rural and urban inpatient facilities. J Electrocardiol. 2023;77:4\u20139. https:\/\/doi.org\/10.1016\/j.jelectrocard.2022.11.008.","journal-title":"J Electrocardiol"},{"issue":"11","key":"1466_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.024338","volume":"11","author":"T Gallo","year":"2022","unstructured":"Gallo T, Heise CW, Woosley RL, et al. Clinician responses to a clinical decision support advisory for high risk of Torsades de Pointes. J Am Heart Assoc. 2022;11(11): e024338. https:\/\/doi.org\/10.1161\/JAHA.122.024338.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1466_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11096-016-0414-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, et al. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39(1):16\u201325.","journal-title":"Int J Clin Pharm"},{"key":"1466_CR17","unstructured":"Woosley RL, Heise CW, Gallo T, Tate J, Woosley D, Romero KA. QTdrugs List. Oro Valley, AZ: AZCERT, Inc. http:\/\/www.CredibleMeds.org. Accessed 28 Nov 2023."},{"issue":"2","key":"1466_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.amjcard.2016.09.041","volume":"119","author":"FS Riad","year":"2017","unstructured":"Riad FS, Andrew M, Davis AM, et al. Drug-induced QTc prolongation. Am J Cardiol. 2017;119(2):280\u20133.","journal-title":"Am J Cardiol"},{"issue":"3","key":"1466_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2125.2008.03357.x","volume":"67","author":"H van der Sijs","year":"2009","unstructured":"van der Sijs H, Kowlesar R, Klootwijk AP, Nelwan SP, Vulto AG, van Gelder T. Clinically relevant QTc prolongation due to overridden drug\u2013drug interaction alerts: a retrospective cohort study. Br J Clin Pharmacol. 2009;67(3):347\u201354. https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03357.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1466_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1074248421995348","volume":"26","author":"ST Simon","year":"2021","unstructured":"Simon ST, Mandair D, Tiwari P, Rosenberg MA. Prediction of drug-induced long QT syndrome using machine learning applied to harmonized electronic health record data. J Cardiovasc Pharmacol Ther. 2021;26(4):335\u201340. https:\/\/doi.org\/10.1177\/1074248421995348.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"1466_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/0018578720965429","volume":"56","author":"B Newell","year":"2021","unstructured":"Newell B, Wirick N, Rigelsky F, Migal K. Implementation of a pharmacist monitoring process for patients on QTc prolonging antibiotics: a pilot study. Hosp Pharm. 2021;56(6):772\u20136. https:\/\/doi.org\/10.1177\/0018578720965429.","journal-title":"Hosp Pharm"},{"issue":"12","key":"1466_CR22","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1111\/bcp.13740","volume":"84","author":"E Vandael","year":"2018","unstructured":"Vandael E, Vandenberk B, Vandenberghe J, Van den Bosch B, Willems R, Foulon V. A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model. Br J Clin Pharmacol. 2018;84(12):2824\u201335. https:\/\/doi.org\/10.1111\/bcp.13740.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01466-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01466-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01466-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T02:15:14Z","timestamp":1731377714000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01466-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1466"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01466-w","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"23 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Bates reports grants and personal fees from EarlySense, personal fees from CDI Negev, equity from ValeraHealth, equity from Clew, equity from MDClone, personal fees and equity from AESOP, personal fees and equity from Feelbetter, equity from Guided Clinical Solutions, and grants from IBM Watson Health, outside the submitted work. Dr. Bates has a patent pending (PHC-028564 US PCT), on intraoperative clinical decision support. Dr. Bates is the Editor-in-Chief of the Journal of Patient Safety. Dr. Bates was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Other authors have no conflict of interest that are relevant to the content of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was deemed exempt by the Mass General Brigham Institutional Review Board (2023P000243) as the study involved only information collection and analysis of identifiable health information for the purposes of secondary research for which consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data of the study is restricted and cannot be shared openly due to the sensitive protected health information which cannot be anonymized including patient identifiers such as birth dates, admission dates and discharge dates.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception; design; and acquisition, analysis, or interpretation of the data. RLW, DLS, MGA, and DWB were responsible for study conception or design. RLW, DLS, and JF did the data cleanup and analysis. RLW, MGA, DLS, AYH, and DWB were responsible for the first draft of the manuscript with all authors reviewing the draft and providing critical feedback. All authors contributed to and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors contributions"}}]}}